Relevant bibliographies by topics / Stage II patients

Academic literature on the topic 'Stage II patients'

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Stage II patients.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Stage II patients"

Warde, P., M. Gospodarowicz, T. Panzarella, C. Catton, J. Sturgeon, M. Moore, and M. Jewett. "Management of stage II seminoma." Journal of Clinical Oncology 16, no. 1 (January 1998): 290–94. http://dx.doi.org/10.1200/jco.1998.16.1.290.

Full text

Abstract:

PURPOSE To assess the results of treatment, patterns of failure, and prognostic factors for relapse in a contemporary cohort of patients with stage II seminoma. MATERIALS AND METHODS From January 1981 and December 1993, 99 patients (median age, 35 years) with stage II seminoma (IIA, 41; IIB, 28; IIC, 24; IID, six) were managed at our institution. Eighty were treated with radiation therapy (RT) and 19 with chemotherapy (ChT). RESULTS With a median follow-up of 6.7 years, the five-year overall actuarial survival was 94%, the 5-year cause-specific survival was 94%, and the 5-year relapse-free rate was 83%. Sixteen (20%) of the 80 patients treated with RT relapsed (median time to relapse, 9 months). Relapse occurred outside the irradiated area in all but two patients. Distant relapse sites included the supraclavicular fossa, bone (four patients, three with spinal cord compression), and lung/mediastinum. All 19 patients treated primarily with ChT achieved disease control and none has relapsed. The relapse rate at 5 years for patients with stage IIA to IIB was 11% (seven of 64), and 56% (nine of 16) for those with stage IIC to IID disease (P < .0001). No patient with IIC or IID disease treated with ChT relapsed as compared with 56% of patients treated with RT (0 of 14 v nine of 16, P = .002). CONCLUSION Radiation therapy is highly effective in patients with stage IIA or IIB seminoma (89% were relapse free). In stage IIC or IID disease, although local control with RT is excellent, a 50% risk of distant relapse is unacceptable, and not all patients who relapse can be salvaged. Chemotherapy should clearly be the primary treatment in patients with stage IIC or IID seminoma.

APA, Harvard, Vancouver, ISO, and other styles

Karsten, Imke E., Gabriele Reinartz, Michaela Pixberg, Kai Kröger, Michael Oertel, Birte Friedrichs, Georg Lenz, and Hans Theodor Eich. "Radiotherapy in Follicular Lymphoma Staged by 18F-FDG-PET/CT: A German Monocenter Study." Biomedicines 9, no. 5 (May 17, 2021): 561. http://dx.doi.org/10.3390/biomedicines9050561.

Full text

Abstract:

This retrospective study examined the role of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in stage-related therapy of follicular lymphomas (FL). Twelve patients each in stages I and II, 13 in stage III and 11 in stage IV were treated in the Department of Radiation Oncology, University Hospital of Muenster, Germany from 2004 to 2016. Radiotherapy (RT), as well as additional chemoimmunotherapy were analyzed with a median follow-up of 87.6 months. Ultrasound (US), CT and 18F-FDG-PET/CT were used to determine progression-free survival (PFS), overall survival (OS) and lymphoma-specific survival (LSS) over 5- and 10- years. 23 of 24 patients with stage I/II (95.8%) had complete remissions (CR) and 17 of 24 patients with stages III/IV FL showed CR (70.8%). 5- and 10-year PFS in stages I/II was 90.0%/78.1% vs. 44.3%/28.5% in stages III/IV. 5- and 10-year OS rates in stages I/II was 100%/93.3% vs. 53.7%/48.4% in stages III/IV. 5- and 10-year LSS of stages I/II was 100%/93.8% vs. 69.2%/62.3% in stages III/IV. FL of stages I/II, staged by 18F-FDG-PET/CT, revealed better survival rates and lower risk of recurrence compared to studies without PET/CT-staging. Especially, patients with PET/CT proven stage I disease showed significantly better survival and lower relapses rates after RT.

APA, Harvard, Vancouver, ISO, and other styles

Liu, Zeming, Xiaopei Shen, Rengyun Liu, Guangwu Zhu, Tao Huang, and Mingzhao Xing. "Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old." Journal of Clinical Endocrinology & Metabolism 104, no. 11 (May 22, 2019): 4941–48. http://dx.doi.org/10.1210/jc.2018-02809.

Full text

Abstract:

Abstract Purpose The mortality risk of stage II differentiated thyroid cancer (DTC) based on the American Joint Committee on Cancer (AJCC) staging system requires further investigation. Methods Retrospective study of DTC in the US Surveillance, Epidemiology, and End Results program for disease-specific mortality risk in various AJCC stages, with patient age stratification of stage II disease. Results Using AJCC staging system 6.0, hazard ratios (HRs) of mortality for stage II DTC in patients <45 yo and patients ≥45 yo and stages III, IVA, IVB, and IVC compared with stage I were 46.95, 4.95, 9.82, 57.37, 222.10, and 468.68, respectively, showing a robustly higher mortality risk in stage II disease in patients <45 yo than in older patients (P < 0.001), comparable with stage IVA (P = 0.482). Similar results were obtained with AJCC 7.0. With AJCC 8.0, HRs of mortality for stage II in patients <55 yo and patients ≥55 yo and stages III, IVA, and IVB compared with stage I were 75.16, 11.23, 69.45, 134.94, and 235.70, respectively, showing a robustly higher risk in stage II disease in patients <55 yo than in older patients (P < 0.001), comparable with stage III (P = 0.57). Kaplan-Meier survival curves displayed a sharp decline with stage II disease in patients <45/55 yo compared with older patients. Conclusions The mortality risk of stage II DTC was sharply differentiated at patient age 45/55 years, being robustly high in younger patients and comparable with stage III/IVA. This emphasizes the importance of considering age when managing stage II DTC and not treating it as a uniformly low-risk disease.

APA, Harvard, Vancouver, ISO, and other styles

Deng, Shengming, Bin Zhang, Yeye Zhou, Xin Xu, Jihui Li, Shibiao Sang, and Wei Zhang. "The Role of18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems." Contrast Media & Molecular Imaging 2018 (July 30, 2018): 1–9. http://dx.doi.org/10.1155/2018/4198673.

Full text

Abstract:

We aimed at comparing the Durie–Salmon Plus (DS Plus) staging system based on Italian Myeloma criteria for PET USe (IMPeTUs) with other two staging systems in predicting prognosis of patients with all stages of newly diagnosed multiple myeloma (MM). A total of 33 MM patients were enrolled in this retrospective study. The variation between the DS Plus classification and Durie–Salmon staging system (DSS) or Revised International Staging System (RISS) classification was assessed. When staged by the DSS, patients in stage I and stage II did not reach the median overall survival (OS), and the median OS was 33 months for stage III (p=0.3621). When staged by the DS Plus, patients in stage I did not reach the median OS of stage I, and the median OS for stages II and III was 38 and nine months, respectively (p=0.0064). When staged by the RISS, patients in stage I did not reach the median OS, and the median OS was 33 and 16 months for stage II and stage III, respectively (p=0.0319). The concordances between two staging systems were 0.07 (DS Plus versus DSS) and 0.37 (DS Plus versus RISS), respectively. Multivariate analysis revealed that DS Plus stage III (HR: 11.539,p=0.021) and the Deauville score of bone marrow ≥4 (HR: 3.487,p=0.031) were independent prognostic factors associated with OS. Both the DS Plus based on IMPeTUs and RISS possessed a better potential in characterizing and stratifying MM patients compared with the DSS. Moreover, DS Plus stage III and the Deauville score of bone marrow ≥4 were reliable prognostic factors in newly diagnosed MM patients.

APA, Harvard, Vancouver, ISO, and other styles

Tataryn, Bohdan, Anna Kryzhanivska, Iryna Dyakiv, and Alina Andriiv. "SURVIVAL OF PATIENTS WITH RECTAL CANCER." Wiadomości Lekarskie 74, no. 9 (2021): 2044–51. http://dx.doi.org/10.36740/wlek202109104.

Full text

Abstract:

The aim: To evaluate the early and late results of treatment of rectal cancer patients after special treatment methods with a view to indentifying optimal method of treatment in correlation with the stage of the disease. Materials and methods: The study is based on the results of observation of 779 patients with stage II, III and IV rectal cancer (RC) who were divided into groups according to the treatment (surgery, surgery + chemotherapy, chemotherapy, surgery + chemotherapy + radiation therapy, radiation therapy + surgery, radiation therapy). Results: According to the results obtained, the overall survival of patients correlates with the stage of rectal cancer: we see the highest percentage of patients’ survival in stage II and, accordingly, the lowest – in stage IV in each of the studied time intervals. Conclusions: The use of combined and integrated treatment in patients with stages II and stage III and the use of chemotherapy in stage IV RC gives a higher rate of cumulative survival of patients at each of the studied intervals

APA, Harvard, Vancouver, ISO, and other styles

Reinhardt, Zdenka, Joseph De Giovanni, John Stickley, Vinay K. Bhole, Benjamin Anderson, Bari Murtuza, Chetan Mehta, Paul Miller, Rami Dhillon, and Oliver Stumper. "Catheter interventions in the staged management of hypoplastic left heart syndrome." Cardiology in the Young 24, no. 2 (February 8, 2013): 212–19. http://dx.doi.org/10.1017/s1047951113000024.

Full text

Abstract:

AbstractAimTo analyse the current practice and contribution of catheter interventions in the staged management of patients with hypoplastic left heart syndrome.MethodsThis study is a retrospective case note review of 527 patients undergoing staged Norwood/Fontan palliation at a single centre between 1993 and 2010. Indications and type of catheter interventions were reviewed over a median follow-up period of 7.5 years.ResultsA staged Norwood/Fontan palliation for hypoplastic left heart syndrome was performed in 527 patients. The 30-day survival rate after individual stages was 76.5% at Stage I, 96.3% at Stage II, and 99.4% at Stage III. A total of 348 interventions were performed in 189 out of 527 patients. Freedom from catheter intervention in survivors was 58.2% before Stage II and 46.7% before Stage III. Kaplan–Meier freedom from intervention post Fontan completion was 55% at 10.8 years of follow-up. Post-stage I interventions were mostly directed to relieve aortic arch obstruction – 84 balloon angioplasties – and augment pulmonary blood flow – 15 right ventricle-to-pulmonary conduit interventions; post-Stage II interventions centred on augmenting size of the left pulmonary artery – 73 procedures and abolishing systemic venous collaterals – 32 procedures. After Stage III, the focus was on manipulating the size of the fenestration – 42 interventions – and the left pulmonary artery −31 procedures.ConclusionInterventional cardiac catheterisation constitutes an integral part in the staged palliative management of patients with hypoplastic left heart syndrome. Over one-third (37%) of patients undergoing staged palliation required catheter intervention over the follow-up period.

APA, Harvard, Vancouver, ISO, and other styles

Novikova, I. A., and O. I. Kit. "Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer." Research and Practical Medicine Journal 8, no. 2 (June 23, 2021): 23–33. http://dx.doi.org/10.17709/2410-1893-2021-8-2-2.

Full text

Abstract:

Purpose of the study. Evaluation of expression of the epithelial-mesenchymal transition markers E-cadherin and ZEB1 in patients with stage II-IV colorectal cancer (CRC).Materials and methods. The study included operational material obtained from 299 patients aged 42–86 years (mean age 64.2±1.7 years) with stage II-IV CRC treated at National Medical Research Centre for Oncology in 2013-2017. Stage II CRC (T3-4 N0 M0 ) was diagnosed in 110 patients, stage III (T1-4 N1-2 M0 ) – in 88 patients, stage IV (T1-4 N0-2 M1 ) – in 101 patients. Polyclonal rabbit antibodies to ZEB1 (Biorbyt Ltd., UK) and mouse monoclonal antibodies to E-cadherin (Diagnostic BioSystems, USA) were used for an IHC analysis. The intensity and degree of tumor cell staining, percentage of stained tumor cells in the sample and the number of patients with positive and negative marker expression were determined. Groups were compared using the Mann–Whitney U test and the Pearson's chi-square test.Results. Positive expression of E-cadherin was found in 64.5 % (193 of 299 patients), ZEB1 – in 80.6 % (241 of 299 patients). The number of patients with E-cadherin-positive tumors statistically significantly decreased (χ2 =15.888 at p<0.001) from stage II to stage IV, while for ZEB1, on the contrary, it statistically significantly increased (χ2 =43.912 at p><0.001) from stage II to stage IV. The mean values of expression in positively stained cells were: in stage II – E-cadherin 55.3±6.8 %, ZEB1 43.0±5.9 %; in stage III – E-cadherin 38.4±5.8 %, ZEB1 77.0±5.5 %; in stage IV – E-cadherin 14.7±4.7 %, ZEB1 76.9±3.5 %. Significant differences were observed between the mean values of ZEB1 expression in stages III and IV compared to stage II, as well as between the mean values of E-cadherin expression in stages II and III compared to stage IV (p><0.05). No significant differences were found in the mean values of ZEB1 and E-cadherin expression in stages III and IV, II and III respectively.Conclusions. The study demonstrated statistically significant relationship between tumor stages and expression of E-cadherin and ZEB1 in the epithelial-mesenchymal transition. The loss of the E-cadherin expression in tumor cells of patients from stage II to stage IV and increased expression of ZEB1 in the studied groups were statistically significant (p<0.05).

APA, Harvard, Vancouver, ISO, and other styles

Chen, Y., W. Xu, S. Zheng, and S. Zhang. "Molecular staging with CM10 ProteinChip and SELDI-MS-TOF for colorectal cancer patients before surgery." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 3612. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3612.

Full text

Abstract:

3612 Background: The objectives of this are to detect the serum proteomic patterns by using SELDI-TOF-MS technology and CM10 ProteinChip in colorectal cancer (CRC) patients, and to evaluate the significance of the proteomic patterns in the tumor staging of colorectal cancer. Methods: SELDI-TOF-MS and CM10 ProteinChip were used to detect the serum proteomic patterns of 76 colorectal cancer patients which including 10 Stage I, 19 Stage II, 16 Stage III and 31 Stage IV patients. Models for various stages were developed and validated by using Support Vector Machine, Discriminant Analysis and time-series analysis methods. Results: The first model, formed by 6 protein peaks (M/Z: 2759.58, 2964.66, 2048.01, 4795.90, 4139.77 and 37761.60 Da), could be used to distinguish local CRC patients (StageIand Stage II) from regional CRC patients (Stage III) with an accuracy of 86.67% (39/45). The second model, formed by 3 protein peaks (M/Z: 6885.30, 2058.32 and 8567.75 Da), could be used to distinguish locoregional CRC patients (Stage I,Stage II and Stage III) from systematic CRC patients (Stage IV) with an accuracy of 75.00% (57/76). The third model could distinguish Stage I from Stage II with an accuracy of 86.21% (25/29). The fourth model could distinguish Stage I from Stage III with an accuracy of 84.62% (22/26). The fifth model could distinguish Stage II from Stage III with an accuracy of 85.71% (30/35). The sixth model could distinguish Stage II from Stage IV with an accuracy of 80.00% (40/50). The seventh model could distinguish Stage III from Stage IV with an accuracy of 78.72% (37/47). All four stages could be distinguished by using a two-dimensional scattered spots figure. Conclusion: We conclude that this method is promising in the staging of colorectal cancer patients before surgery. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

Bertelsen, K., B. HØLund, J. E. Andersen, K. Nielsen, I. StrØYer, and P. Ladehoff. "Prognostic factors and adjuvant treatment in early epithelial ovarian cancer." International Journal of Gynecologic Cancer 3, no. 4 (1993): 211–18. http://dx.doi.org/10.1046/j.1525-1438.1993.03040211.x.

Full text

Abstract:

Four hundred and ten patients with epithelial ovarian cancer FIGO stages I and II were registered by a Danish multicenter study group (The Danish Ovarian Cancer Group - DACOVA). Two-thirds were stage I, the most frequent substage was Iai which was the classification in 27%. Five-year survival for stage I was 72%, and 38% for stage II. Multivariate analysis showed that age, stage, residual tumor, histologic grade and adjuvant treatment had prognostic value. For stage, three significantly different groups could be identified: (1) stage Iai, (2) stage Iaii-Ic, and (3) stage II. Histologic grade showed a significant survival difference between all grades. Adjuvant treatment had a moderate but significant impact on survival. Patients in stage Iai had a good survival with surgery alone and will probably not benefit from adjuvant therapy. Adjuvant treatment improved survival for the remaining patients in stages I and II without residual tumor. A difference between treatment modalities was not observed. However, the data need to be confirmed by a randomized trial. Patients in stage II with residual tumor should be treated as stage III.

APA, Harvard, Vancouver, ISO, and other styles

Connors, Joseph M., Randy D. Gascoyne, Paul Hoskins, James Morris, Tom Pickles, Laurie Sehn, Tamara Shenkier, Richard Klasa, Nicholas Voss, and Kerry Joanne Savage. "Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials." Blood 116, no. 21 (November 19, 2010): 417. http://dx.doi.org/10.1182/blood.v116.21.417.417.

Full text

Abstract:

Abstract Abstract 417 Background: Trials enrolling patients with limited stage Hodgkin lymphoma conducted by European cooperative groups including EORTC, GELA and the GHSG frequently include patients with stage II B or stage II bulky (≥ 10 cm) disease in either “favorable” or “unfavorable” subgroups. Similar patients are usually excluded from North American trials of limited stage disease and rather are included in trials of advanced stage lymphoma. We sought to clarify the appropriateness of these approaches. Methods: All adult (age > 15 but < 66 y) HIV antibody negative patients with stage II A bulky, II B non-bulky or II B bulky Hodgkin lymphoma treated in British Columbia since 1981, when ABVD-type chemotherapy became standard, were identified using the BC Cancer Agency Lymphoid Cancer Database. Characteristics: n=416; male 54%; age range 16–64 y (median = 30); histologic subtype nodular sclerosis 86%, mixed cellularity 5%, not subclassifiable 6%, other 3%; subdiaphragmatic 3%; stage II A bulky 32%, II B non-bulky 32%, II B bulky 36%; localized extranodal extension (E lesion) 35%; largest mass diameter non-bulky range 1–9 cm (median 6 cm), bulky range 10–25 cm (median 12 cm); IPFP prognostic score 0, 9%; 1, 33%; 2, 32%; 3, 19%; 4, 6%; 5, 1% (data missing 36%). Results: Planned treatment consisted of 6–8 cycles of ABVD-type chemotherapy followed by radiation for a persistent residual mass (only if PET positive since 2005). 50% of patients received radiation (extended field 24%, involved field 76%). Thus, patients were treated with the same approach that is used for stage III or IV. Patients with bulky disease were much more likely to receive radiation: II A bulky 72%; II B non-bulky 11%; II B bulky 65%. For all 416 patients, with a median follow-up of 8 y, 5 and 10 y progression free survivals (PFS) were 81% and 76%; time-to-progression (TTP) estimates 83% and 81% (Fig. 1); and overall survivals (OS) were 94% and 90%. Although there is some variation, survivals were very similar across the three stage groups. This experience is instructive and indicates that when patients with stage II B bulky or non-bulky or stage II A bulky Hodgkin lymphoma are treated with the same approach as is used for advanced stage disease at least 20% of patients relapse. Conclusion: It is inappropriate to include patients with stage II B or stage II A bulky Hodgkin lymphoma on trials designed for limited stage disease. With an estimated relapse rate of at least 20% inclusion of these patients can grossly distort outcomes and compromise interpretation of the results of the trial since the expectation for the rest of the patients (stage I A and II A, low bulk) is that no more than 5% of patients will relapse. Patients with stage II B or stage II A bulky Hodgkin lymphoma should be included in trials for patients with advanced stage disease. Disclosures: Klasa: Seattle Genetics, Inc.: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Stage II patients"

Tsikitis, Vassiliki, David Larson, Marianne Huebner, Christine Lohse, and Patricia Thompson. "Predictors of recurrence free survival for patients with stage II and III colon cancer." BioMed Central, 2014. http://hdl.handle.net/10150/610351.

Full text

Abstract:

BACKGROUND:The aim of this study was to evaluate clinico-pathologic specific predictors of recurrence for stage II/III disease. Improving recurrence prediction for resected stage II/III colon cancer patients could alter surveillance strategies, providing opportunities for more informed use of chemotherapy for high risk individuals.METHODS:871 stage II and 265 stage III patients with colon cancers were included. Features studied included surgery date, age, gender, chemotherapy, tumor location, number of positive lymph nodes, tumor differentiation, and lymphovascular and perineural invasion. Time to recurrence was evaluated, using Cox's proportional hazards models. The predictive ability of the multivariable models was evaluated using the concordance (c) index.RESULTS:For stage II cancer patients, estimated recurrence-free survival rates at one, three, five, and seven years following surgery were 98%, 92%, 90%, and 89%. Only T stage was significantly associated with recurrence. Estimated recurrence-free survival rates for stage III patients at one, three, five, and seven years following surgery were 94%, 78%, 70%, and 66%. Higher recurrence rates were seen in patients who didn't receive chemotherapy (p=0.023), with a higher number of positive nodes (p<0.001). The c-index for the stage II model was 0.55 and 0.68 for stage III.CONCLUSIONS:Current clinic-pathologic information is inadequate for prediction of colon cancer recurrence after resection for stage II and IIII patients. Identification and clinical use of molecular markers to identify the earlier stage II and III colon cancer patients at elevated risk of recurrence are needed to improve prognostication of early stage colon cancers.

APA, Harvard, Vancouver, ISO, and other styles

Dobriansky, V. V. "Risk factors for recurrent hypoglycemia in patients with type II diabetes mellitus in the prehospital stage." Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19824.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Obayashi(Nishiuchi), Aya. "MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer." Kyoto University, 2020. http://hdl.handle.net/2433/253179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Brand, Juanita M. "The lived experiences of six women during adjuvant chemotherapy for Stage I or II breast cancer." Virtual Press, 2005. http://liblink.bsu.edu/uhtbin/catkey/1317926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Caie, Peter David. "Discovery of novel prognostic tools to stratify high risk stage II colorectal cancer patients utilising digital pathology." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/19527.

Full text

Abstract:

Colorectal cancer (CRC) patients are stratified by the Tumour, Node and Metastasis (TNM) staging system for clinical decision making. Additional genomic markers have a limited utility in some cases where precise targeted therapy may be available. Thus, classical clinical pathological staging remains the mainstay of the assessment of this disease. Surgical resection is generally considered curative for Stage II patients, however 20-30% of these patients experience disease recurrence and disease specific death. It is imperative to identify these high risk patients in order to assess if further treatment or detailed follow up could be beneficial to their overall survival. The aim of the thesis was to categorise Stage II CRC patients into high and low risk of disease specific death through novel image based analysis algorithms. Firstly, an image analysis algorithm was developed to quantify and assess the prognostic value of three histopathological features through immuno-fluorescence: lymphatic vessel density (LVD), lymphatic vessel invasion (LVI) and tumour budding (TB). Image analysis provides the ability to standardise their quantification and negates observer variability. All three histopathological features were found to be predictors of CRC specific death within the training set (n=50); TB (HR =5.7; 95% CI, 2.38-13.8), LVD (HR =5.1; 95% CI, 2.04-12.99) and LVI (HR =9.9; 95% CI, 3.57- 27.98). Only TB (HR=2.49; 95% CI, 1.03-5.99) and LVI (HR =2.46; 95%CI, 1 - 6.05), however, were significant predictors of disease specific death in the validation set (n=134). Image analysis was further employed to characterise TB and quantify intra-tumoural heterogeneity. Tumour subpopulations within CRC tissue sections were segmented for the quantification of differential biomarker expression associated with epithelial mesenchymal transition and aggressive disease. Secondly, a novel histopathological feature ‘Sum Area Large Tumour Bud’ (ALTB) was identified through immunofluorescence coupled to a novel tissue phenomics approach. The tissue phenomics approach created a complex phenotypic fingerprint consisting of multiple parameters extracted from the unbiased segmentation of all objects within a digitised image. Data mining was employed to identify the significant parameters within the phenotypic fingerprint. ALTB was found to be a more significant predictor of disease specific death than LVI or TB in both the training set (HR = 20.2; 95% CI, 4.6 – 87.9) and the validation set (HR = 4; 95% CI, 1.5 – 11.1). Finally, ALTB was combined with two parameters, ‘differentiation’ and ‘pT stage’, which were exported from the original patient pathology report to form an integrative pathology score. The integrative pathology score was highly significant at predicting disease specific death within the validation set (HR = 7.5; 95% CI, 3 – 18.5). In conclusion, image analysis allows the standardised quantification of set histopathological features and the heterogeneous expression of biomarkers. A novel image based histopathological feature combined with classical pathology allows the highly significant stratification of Stage II CRC patients into high and low risk of disease specific death.

APA, Harvard, Vancouver, ISO, and other styles

Hendrix, Ryan J. "Improved Survival after Administration of Neoadjuvant Chemotherapy in Patients with Clinical Stage I/II Pancreatic Ductal Adenocarcinoma." eScholarship@UMMS, 2019. https://escholarship.umassmed.edu/gsbs_diss/1029.

Full text

Abstract:

Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of US cancer related deaths. This study assessed the oncologic benefit of a neoadjuvant chemotherapy (NAC) treatment strategy for patients with clinical Stage I/II PDAC. Methods: Patients with biopsy confirmed PDAC and clinical Stage I/II disease were treated with a protocol of NAC. The primary study endpoint was median overall survival (OS). Kaplan-Meier survival curves were compared using the log-rank test. Results: 56 patients met inclusion criteria. Of these, 21 patients (38%) had Stage I disease and 35 (62%) had Stage II disease. The median OS for the entire study population was 18.7 months. A total of 22 (39%) patients were managed with NAC+S; 34 (61%) received NAC alone. Median OS and 2-year survival rates were greater in those completing NAC+S compared to NAC alone (median OS 28.8 months vs. 17.3 months: p=0.05; 2-year OS: 55% vs 21%: p=0.01) . Interestingly, patients managed with NAC who were not candidates for surgical resection after restaging demonstrated a survival advantage (17.3 months) compared to what was previously reported in historical controls. Conclusion: NAC+S provided a significant 11.5 month improvement in median OS compared to treatment with NAC alone. Modern NAC may contribute a significant oncologic benefit in the overall treatment strategy for patients with Stage I/II PDAC, even if surgery is not ultimately pursued.

APA, Harvard, Vancouver, ISO, and other styles

Morris, Melinda. "Clinical and pathological predictors of survival for stage II and III colon cancer patients treated with or without chemotherapy : a population-based study." University of Western Australia. School of Surgery and Pathology, 2007. http://theses.library.uwa.edu.au/adt-WU2008.0012.

Full text

Abstract:

[Truncated abstract] Clinical and pathological predictors of survival for stage II and III colon cancer patients treated with or without chemotherapy: a population-based study. Aim: Using a population-based cohort of colorectal cancer (CRC), the major aims of this study were to: 1. Identify clinico-pathological markers that can be used to define a subset of stage II colon cancer patients with excellent prognosis and who therefore do not require referral for adjuvant chemotherapy; 2. Investigate whether there is a survival benefit from the use of adjuvant chemotherapy in a population-based cohort of stage II colon cancer; 3. Investigate stage III colon cancer patients for evidence of predictive markers for response to 5FU chemotherapy; 4. Investigate CRC for age-related differences in clinico-pathological and molecular features. Hypotheses to be tested: 1. A subset of good prognosis stage II colon cancers can be defined using routine pathological markers; 2. Females colon cancer patients gain more survival advantage from 5FU chemotherapy than males; 3. Tumours from young CRC patients have different molecular characteristics to those from older patients; 4. The underlying molecular characteristics of tumour can impact upon the response to 5FU chemotherapy. Methods: The study cohort consisted of 5,971 cases diagnosed between 1993 and 2003 representing over 90% of the CRCs diagnosed in the state of Western Australia. Results: The major findings of this translational research into colon cancer can be summarized as follows: The morphological features of serosal and vascular invasion allow for prognostic stratification of stage II colon cancer into

APA, Harvard, Vancouver, ISO, and other styles

Schrama, Jolanda Godefrida. "Patient selection for high-dose chemotherapy in stage II and IV breast cancer." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2004. http://dare.uva.nl/document/75451.

Full text

APA, Harvard, Vancouver, ISO, and other styles

MAIGNE, PHILIPPE. "Traitement de la maladie de hodgkin stade i-ii par radiotherapie exclusive : a propos de 67 patients du centre claudius regaud." Toulouse 3, 1993. http://www.theses.fr/1993TOU31057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

POURRAT, CHABROLET CORINNE. "Arteriopathie obliterante des membres inferieurs et hypertension arterielle : suivi longitudinal sur 10 ans d'une population de 125 patients du stade ii ; royat 1984-1993." Clermont-Ferrand 1, 1994. http://www.theses.fr/1994CLF1M026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Stage II patients"

Larsen, Earnest. Stage II recovery: Life beyond addiction. Minneapolis, Minn: Winston Press, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Health, Illinois Department of Public. Title II comprehensive plan for HIV/AIDS services in Illinois, 2006-2008 / State of Illinois, Department of Public Health. [Springfield, Ill.]: State of Illinois, Dept. of Public Health, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Puig, Ana. Efficacy of Art Therapy to Enhance Emotional Expression Spirituality and Psychological Well-Being of Newly Diagnosed Stage I and Stage II Breast Cancer Patients. Creative Media Partners, LLC, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Puig, Ana. The Efficacy of Art Therapy to Enhance Emotional Expression Spirituality and Psychological Well-being of Newly Diagnosed Stage I and Stage II Breast Cancer Patients. Dissertation Discovery Company, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Stage loading versus progressive loading in cardiac rehabilitation functional evaluation: Comparison of the Bruce and Roy ramp treadmill protocols on post-Phase II CAD patients. 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Stage loading versus progressive loading in cardiac rehabilitation functional evaluation: Comparison of the Bruce and Roy ramp treadmill protocols on post-Phase II CAD patients. 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Stage loading versus progressive loading in cardiac rehabilitation functional evaluation: Comparison of the Bruce and Roy ramp treadmill protocols on post-Phase II CAD patients. 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Ali-Fehmi, Rouba, and Eman Abdulfatah. Biological Aspects and Clinical Applications of Serum Biomarkers in Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0002.

Full text

Abstract:

Ovarian cancer, the most aggressive gynecological malignancy, presents at advanced stages with metastatic disease. Diagnosis at an early stage is the most important determinant of survival; however, the majority of patients are asymptomatic at early stages and the current diagnostic tools used in clinics show limited success in early detection and hence the need for new diagnostic biomarkers. With the advance of techniques in genomic and proteomics, numerous biomarkers are emerging which may serve as a platform for early detection of ovarian cancer. These include gene-, protein-, miRNAs, and metabolite- based biomarkers. Examples of gene-based biomarkers include HE4, FLOR1, p16INK4a, BRCA1, BRCA2, MLH1, and MSH2. Protein- based biomarkers include leptin, prolactin, osteopontin, IGF-II, and MIF. This chapter discusses the serum tumor markers (CA-125) in current use for screening, diagnosis and monitoring of ovarian cancer as well as the novel biomarkers that are under investigation and validation.

APA, Harvard, Vancouver, ISO, and other styles

Barsoum, Rashad S. Schistosomiasis. Edited by Vivekanand Jha. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0194_update_001.

Full text

Abstract:

The urinary system is the primary target of Schistosoma haematobium infection, which leads to granuloma formation in the lower urinary tract that heals with fibrosis and calcification. While the early lesions may be associated with distressing acute or subacute symptoms, it is the late lesions that constitute the main clinical impact of schistosomiasis. The latter include chronic cystitis, ureteric fibrosis, ureterovesical obstruction or reflux which may lead to chronic pyelonephritis. Secondary bacterial infection and bladder cancer are the main secondary sequelae of urinary schistosomiasis.The kidneys are also a secondary target of S. mansoni infection, attributed to the systemic immune response to the parasite. Specific immune complexes are responsible for early, often asymptomatic, possibly reversible, mesangioproliferative lesions which are categorized as ‘class I’. Subsequent classes (II–VI) display different histopathology, more serious clinical disease, and confounding pathogenic factors. Class II lesions are encountered in patients with concomitant salmonellosis; they are typically exudative and associated with acute-onset nephrotic syndrome. Classes III (mesangiocapillary glomerulonephritis) and IV (focal segmental sclerosis) are progressive forms of glomerular disease associated with significant hepatic pathology. They are usually associated with immunoglobulin A deposits which seem to have a significant pathogenic role. Class V (amyloidosis) occurs with long-standing active infection with either S. haematobium or S. mansoni. Class VI is seen in patients with concomitant HCV infection, where the pathology is a mix of schistosomal and cryoglobulinaemic lesions, as well as amyloidosis which seems to be accelerated by the confounded pathogenesis.Early schistosomal lesions, particularly those of the lower urinary tract, respond to antiparasitic treatment. Late urological lesions may need surgery or endoscopic interventions. As a rule, glomerular lesions do not respond to treatment with the exception of class II where dual antiparasitic and antibiotic therapy is usually curative. Patients with end-stage kidney disease may constitute specific, yet not insurmountable technical and logistic problems in dialysis or transplantation. Recurrence after transplantation is rare.

APA, Harvard, Vancouver, ISO, and other styles

Krauter, Cheryl. Psychosocial Care of Cancer Survivors. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190636364.001.0001.

Full text

Abstract:

Psychosocial Care of Cancer Survivors: A Clinician’s Guide and Workbook for Providing Wholehearted Care is a clinical resource written for healthcare practitioners with the goal of helping them enhance communication with both patients and colleagues. It addresses questions of how to bring a humanistic approach and quality attention to the growing needs of patients in the post-treatment phase of a cancer diagnosis. As a workbook, it is both a guide and an applicable resource for daily clinical practice. It provides a needed structure for clinicians to help them reconnect with the meaningful aspects of their work. Part I focuses on skillful means for providing humanistic, person-centered care. Part II offers clinicians pragmatic structures and methods they can start using with patients right away and provides a humanistic clinical framework that benefits them both personally and professionally: clinical skills vital to forming healing clinical relationships (e.g., the four C’s of communication: communication, curiosity, concern, conversation; communication tools to enhance effective collaboration, such as personal and professional boundaries, the essentials of a healing relationship, stages of the clinical interview, collegial collaboration; exercises designed for personal reflection and the implementation of the clinical skills and communication tools mentioned; and useful practices and solutions to increase the efficacy of and satisfaction with their work.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Stage II patients"

Jenkins, David. "Stage II: Background History." In Listening to Gynaecological Patients’ Problems, 9–10. London: Springer London, 1999. http://dx.doi.org/10.1007/978-1-4471-0553-4_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Gröne, J., D. Lenze, H. Seidel, U. Mansmann, H. J. Buhr, and M. Hummel. "Correlation of molecular profiles and clinical course of stage II colon cancer patients." In Deutsche Gesellschaft für Chirurgie, 105–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-00625-8_40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kollmannsberger, Christian, and Carsten Bokemeyer. "Treatment of Patients with Stage II A/B and Advanced Nonseminomatous Germ Cell Tumors." In Cancer of the Testis, 185–95. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84800-370-5_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Pelayo, Ana Paula, Montserrat Pelayo, and Gabriela Duran-Aguilar. "Improvement in the Quality of Life of Patients with End-Stage Renal Failure Who Live Without Replacement Therapy in Mexico." In Human Systems Engineering and Design II, 365–69. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-27928-8_56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Micu, Bogdan Vasile, C. M. Micu, D. Chirila, H. Silaghi, D. R. Miclaus, M. S. Muresan, T. R. Pop, N. Constantea, and C. Ionescu. "Prognostic Implications of Sentinel Lymph Node Mapping in Stage I and II Colorectal Cancer Patients." In 6th International Conference on Advancements of Medicine and Health Care through Technology; 17–20 October 2018, Cluj-Napoca, Romania, 301–4. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-6207-1_47.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dukat, A., P. Gavornik, J. Kolesar, and Z. Mikes. "Exercise Programme of Patients with Ischaemic Disease of Lower Limbs Stage II–III — Evaluation with Holter ECG Monitorings." In Advances in Ergometry, 79–81. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76442-4_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Kirsch, Brian James, Shu-Jyuan Chang, Michael James Betenbaugh, and Anne Le. "Non-Hodgkin Lymphoma Metabolism." In The Heterogeneity of Cancer Metabolism, 103–16. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65768-0_7.

Full text

Abstract:

AbstractNon-Hodgkin lymphomas (NHLs) are a heterogeneous group of lymphoid neoplasms with different biological characteristics. About 90% of all lymphomas in the United States originate from B lymphocytes, while the remaining originate from T cells [1]. The treatment of NHLs depends on the neoplastic histology and stage of the tumor, which will indicate whether radiotherapy, chemotherapy, or a combination is the best suitable treatment [2]. The American Cancer Society describes the staging of lymphoma as follows: Stage I is lymphoma in a single node or area. Stage II is when that lymphoma has spread to another node or organ tissue. Stage III is when it has spread to lymph nodes on two sides of the diaphragm. Stage IV is when cancer has significantly spread to organs outside the lymph system. Radiation therapy is the traditional therapeutic route for localized follicular and mucosa-associated lymphomas. Chemotherapy is utilized for the treatment of large-cell lymphomas and high-grade lymphomas [2]. However, the treatment of indolent lymphomas remains problematic as the patients often have metastasis, for which no standard approach exists [2].

APA, Harvard, Vancouver, ISO, and other styles

Beelen, D. W., K. Quabeck, U. Graeven, H. G. Sayer, and U. W. Schaefer. "Influence of Treatment Modality, Patient/Donor Characteristics, and Disease Stage on the Risk of Relapse After Allogeneic Marrow Transplantation for Acute Leukemia." In Acute Leukemias II, 688–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Pfannstiel, Mario A. "State of the Art von Maßnahmen und Instrumenten zum Management der Patienten- und Mitarbeiterdiversität im Krankenhaus." In Dienstleistungsmanagement im Krankenhaus II, 381–427. Wiesbaden: Springer Fachmedien Wiesbaden, 2014. http://dx.doi.org/10.1007/978-3-658-05134-1_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Pilar Vela-Orús, Maria, and María Sonia Gaztambide-Sáenz. "Chronic Limb-Threatening Ischemia (CLTI) in Diabetic Patients: Looking at the Big Picture beyond Wound, Ischemia and Foot Infection (WIfI) Classification System." In The Eye and Foot in Diabetes. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.91970.

Full text

Abstract:

During the 1990s, most diabetic ulcers were considered neuropathic, but the Eurodiale study showed that more than 50% of these were non-plantar (neuro-ischaemic and ischaemic). According to the International Guidelines, the neuro-ischaemic and ischaemic diabetic foot ulcer (DFU) outcomes are connected to factors related to the wound, leg-associated factors and patients’ comorbidities. We used wound, ischaemia and foot infection (WIfI) classification system; Trans-Atlantic Inter-Society Consensus-II (TASC-II) arterial lesion score; and Kaiser Permanente pyramid (stratification of patients according to their complexity) for assessing these parameters. From February 2011 to June 2012, we collected 124 episodes of neuro-ischaemic and ischaemic active ulcer in 100 patients: 18 required major amputation, 14 of them were in WIfI stage 4 and 4 in WIfI stage 3. Ten patients (over 14 in WIfI stage 4) were classified as TASC-II D. Eight patients (over the same 14) were classified as the higher risk of Kaiser Permanente pyramid. In line with other studies, our data support that the WIfI classification correlates well regarding risk of amputation at 1 year. However, when adding TASC-II and Kaiser Permanente pyramid assessment, the outcome is even more accurate not only for limb salvage but also for patients’ survival.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Stage II patients"

Spratley, Edward M., Erika A. Matheis, Curtis W. Hayes, Robert S. Adelaar, and Jennifer S. Wayne. "Patient Specific Modeling of a Stage II Flatfoot Population." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14165.

Full text

Abstract:

Adult Acquired Flatfoot Deformity (AAFD) is a degenerative disease characterized by chronic changes in the joint alignment of the bones of the foot leading to significant pain and dysfunction. The hallmark of this disease is the functional loss in posterior tibialis tendon (PTT) strength though mechanical degradation of passive support structures of the foot have also been implicated, namely the spring ligament, talocalcaneal interosseous ligaments, fibers of the anterior deltoid, and the long and short plantar ligaments. [1] Clinically, AAFD patients present with midfoot collapse, forefoot abduction, and valgus tilting of the hindfoot and the magnitudes of these deformities are most often graded using plane radiographs in the mediolateral (ML), oblique anteroposterior (AP) and posteroanterior (PA) views. [1–3] The objective of this study was to develop a population of patient-matched rigid-body kinematic models using a standardized methodology that can be used to predict pathologic foot function with agreement between patient and model assessed through clinically relevant radiographic joint angles.

APA, Harvard, Vancouver, ISO, and other styles

Teixeira, Marina Diogenes, Felipe Andreotta Cavagna, Jorge Yoshinori Shida, Andre Mattar, and Luiz Henrique Gebrim. "BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II AND III TREATED IN THE PUBLIC HEALTH SYSTEM." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1067.

Full text

Abstract:

Introduction: Over the last few decades, neoadjuvant chemotherapy (NCT) has played an increasing role in the management of breast cancer. It allows for an evaluation of the tumour reponse in vivo and may afford a de-escalation of surgeries. Despite advances in neoadjuvant treatment, evidence shows that rates of breast-conserving surgeries (BCT) after NCT are low (51%–68%) even when a patient is eligible for a less agressive surgery. Objectives: To analyze the surgical treatment performed in patients who underwent NCT in clinical stages (CS) II or III within a public health service in Brazil. Methods: A cross-sectional study was conducted with statistical analysis of the database of a public hospital in São Paulo with 11,073 patients treated from January 2009 to December 2020. Results: A total of 11,073 patients with breast cancer were treated in this period and 9,526 surgeries were performed, from which 4,613 (48.4%) were BCS and 4,913 (51.6%) were mastectomies. Among these procedures, 2,231 patients underwent NCT before surgical treatment, 275 (12%) were submitted to BCS and 1,956 (88%) to mastectomy. When compared by clinical stages: 641 were in CS II, BCS was performed in 143 (22.3%) and mastectomy in 498 (77.7%), and 1,590 were in CS III, from which 132 (8.3%) were submitted to BCS and 1,458 (91.7%) to mastectomy after neoadjuvant treatment. Conclusions: We observed that the rate of BCS after NCT in patients in CS II or III in our service was even lower than that found in the international literature. Some of the factors that may have influenced this result are: patient preference, anatomical extension of the tumor with skin ulceration (T4b), physician insecurity in performing a less aggressive treatment or difficulty accessing radiotherapy for patients from distant cities. This suggests that the potential surgical benefits of NCT are not being fully understood or explored. There is a need to resolve the uncertainties that are are holding back surgical teams from adopting more conservative surgeries.

APA, Harvard, Vancouver, ISO, and other styles

Jain, Vandana, Rupinder Sekhon, Shveta Giri, and Sudhir Rawal. "Role of radical surgery in early stages of vaginal cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685350.

Full text

Abstract:

Objectives: The objective of our present study was to evaluate the efficacy of radical vaginectomy with or without radical hysterectomy in patients with FIGO stage I and II vaginal cancers. Materials and Methods: A retrospective study was carried out on 13 patients aged 35 – 78 years. All the patients underwent radical surgery for vaginal cancer from April 2010 till June 2015. Kaplan- meier analyses was used to calculate the disease free survival and overall survival at 12 months. Results: The mean age of patients was 54.9 years. Twelve patients were with FIGO stage I while one had stage II vaginal cancer. The histopathology was squamous cell cancer in 9 patients, small cell neuroendocrine cancer in two patients and malignant melanoma in 2 patients. The lesion was confined to upper 2/3 of vagina in 8 cases and lower 1/3 was involved in 5 cases. All the patients underwent radical surgery. Lymph node dissection was done in eleven patients out of whom lymph nodes were positive in 4 patients. Three patients had positive margins. Adjuvant treatment was given to patients with positive margins or positive nodes. Six patients did not require any adjuvant treatment and two patients defaulted adjuvant treatment. One patient developed Vesico-vaginal fistula. Over a follow up period ranging from 6 to 67 months, recurrence developed in two patients and one of them died of disease. The 12 months Disease free survival was 82.1% and 12 months Overall Survival was 90.9%. Conclusion: Stage I and selected stage II vaginal cancer patients have good outcomes in terms of survival and local tumor control if managed judiciously by initial surgery followed by selective adjuvant therapy.

APA, Harvard, Vancouver, ISO, and other styles

Rettke, S. R., C. A. Owen, E. J. W. Bowie, T. L. Cole, R. H. Wiesner, R. A. F. Krom, and C. Jensen. "HEMOSTATIC EVALUATION OF PATIENTS UNDERGOING LIVER TRANSPLANTATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643070.

Full text

Abstract:

Significant hemostatic abnormalities can occur during orthotopic liver transplantation (OLT). This study addressed three goals: 1)evaluation of the hemostatic mechanism at each stage of the OLT; 2) the relationship of the coagulation process with the thrombelastograph (TEG); and 3) comparison of results in patients requiring retransplantation or who died, with the overall pattern. To evaluate hemostasis during 50 consecutive OLTs, a detailed coagulation and TEG study was done. The surgical procedure was divided into the following stages: Stage I--induction of anesthesia to occlusion of blood flow to the patient’ s diseased liver; Stage II—occlusion of blood flow to the patient’ s diseased liver to reperfusion of the patient’ s new liver; and Stage III—reperfusion of the new liver until skin closure. 28 ml of arterial blood were sampled at the beginning and end of each stage and up to five days posttransplantation for the following: platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, prothrombin, factors V, VII, IX, and X, plasminogen, antiplasmin, antithrombin III (functional and immunologic), fibrinolytic split products, and TEG. The patient’ s core temperature and amount of blood products transfused were obtained intraoperatively during each of the six data times. The ischemia time of the donor liver was recorded. Significant hemostatic abnormalities developed during each of the 50 OLTs, especially during reperfusion of the donor liver. In some instances, this was corrected within one hour, but platelet counts continued to fall, and a number of coagulation factors rebounded only partially. The TEG values correlated with laboratory data and blood loss, but the correlations were not strong. The patient’ s requirement for red cells varied with the operative drop in temperature; however, the donor liver ischemia time and length of Stage II made no significant difference. It is concluded that 1) significant deterioration of coagulation factors occurs during OLT, 2) the TEG is an effective screening test that affords prompt information, 3) aggressive measures should be taken to maintain the patient’ s body temperature at 37°C, 4) patient outcome was not predicted by intraoperative hemostatic evaluation.

APA, Harvard, Vancouver, ISO, and other styles

Smid, Dionne, Frits Franssen, Sarah Wilke, Jean Muris, Gernot Rohde, Paul Jones, Emiel Wouters, and Martijn Spruit. "Characterization of patients with COPD GOLD stage I and II referred for pulmonary rehabilitation." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa3696.

Full text

APA, Harvard, Vancouver, ISO, and other styles

O'Donnell, Denis E., Francois Maltais, Janos Porszasz, Frank Albers, Qiqi Deng, Gemzel Hernandez, Ahmar Iqbal, Heather Paden, and Richard Casaburi. "Lung Function And Exercise Impairment In Patients With GOLD Stage I And II COPD." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Batista, Maria Stefania Nóbrega, and Lara Moreira Mendes Carneiro. "Principles of palliative therapy in the care of patients with metastatic breast cancer." In II INTERNATIONAL SEVEN MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/homeinternationalanais-039.

Full text

Abstract:

Abstract Breast cancer is the leading cause of cancer death in the female population in all regions of Brazil, except in the North, where cervical cancer occupies this position. The mortality rate due to breast cancer, adjusted by the world population, was 14.23 deaths/100,000 women in 2019, with the highest rates in the Southeast and South regions, with 16.14 and 15.08 deaths/100,000 women, respectively. Considering the increase in the number of cases of cancer – especially breast cancer – part of them in advanced stage and without possibility of cure, that is, metastatic, it is evident the need and importance of palliative care (PC) that aim comfort and management at the end of the life of cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

Thie, A., T. h. Henze, D. Deggar, M. Obering, R. Clemers, H. J. Kleinz, and G. F. Lombard. "FACTOR XIII CONCENTRATE FOR PROPHYLAXIS OF REBLEEDING IN SUBARACHNOID HEMORRHAGE (SAH) - RESULTS OF A PROSPER TIVE MULTICENTER PILOT STUDY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643312.

Full text

Abstract:

Rebleeding occurs in subarachnoid hemorrhage (SAH) in 20 - 25 % of patients, with a mortality rate being above 50 %. The cause of rebleeding is considered to be premature fibrinolysis of the fibrin clot surrounding the site of rupture. Since the stability of the fibrin clot is influenced by the activity of coagulation factor XIII, and moreover, a factor XIII deficiency has been reported in SAH patients, the question arises as to whether the incidence of rebleeding can be influenced by the administration of F XIII concentrate.During a period of 6 months, 69 patients with acute SAH were enlisted in an open, prospective, multicenter study. On admission, 5 patients were classified as stage I (7.2%) according to the Hunt and Hess scale, 22 as stage III (31.9%), 11 as stage IV (16%) and 9 as stage V (13%). Aneurysm was confirmed by angiography in 52 patients (75%). All the patients received 10 x 1250 U F XIII concentrate during the first 15 days after the initial hemorrhage. Surgery on the aneurysm was performed between day 3 and 32 (median: day 13) in 35 patients.A total of 7 rebleedings occurred in 6 patients (8.7%), of whom 2 were stage I - II and 4 were stage III - V cases. Cerebral infarction was observed in 10 patients (14.5%), and hydrocephalus requiring shunting occurred in 1 patient. There were no cases of peripheral thromboses or embolisms. After 4 weeks, the overall mortality rate was 26%. (stage I - II: 11.1%, stage III - V: 37.5%).The conventional approach in the prophylaxis of rebleeding in SAH is an early operation or intravenous administration of antifibrinolytics. However, as none of these measures significantly reduce overall mortality, the present pilot study investigated a new, therapeutic approach in which F XIII concentrates were administered in order to stabilize the fibrin clots and prevent premature fibrinolysis. The data so far show that Fibrogammin P is an effective and well tolerated agent for the prophylaxis of post-SAH rebleeding. In order to statistically confirm the results of the pilot study, we have, in the meantime, started a prospective, randomized, placebo-controlled, multicenter double-blind study, which will involve 750 patients over a period of 2 years.

APA, Harvard, Vancouver, ISO, and other styles

Faria, Tayana Moreira, Felipe Andreotta Cavagna, André Mattar, Jorge Yoshinori Shida, and Luiz Henrique Gebrim. "AVERAGE SURVIVAL ACCORDING TO THE CLINICAL STAGE IN 10,532 PATIENTS WITH BREAST CANCER TREATED BY THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS) FROM JANUARY 2011 TO DECEMBER 2019 AT PÉROLA BYINGTON HOSPITAL." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1034.

Full text

Abstract:

Introduction: The distribution of the different clinical stages of cancer in the population is of paramount importance not only to assess prognosis and therapy, but mainly to establish public health strategies and priorities. The prevalence of advanced cases in some populations shows the need for public assistance policies aimed at early detection for a rapid reduction in mortality. Unfortunately, reports in Brazil about the different realities of assistance in the Brazilian Unified Health System (SUS) are scarce. Objectives: To evaluate the distribution of the different clinical stages, and the mean 5-year survival of 10,532 breast cancer patients treated by SUS at Pérola Byington Hospital, from January 2011 to December 2016. Methods: A hospital-based observational cross-sectional study was conducted. The population consisted of women with breast cancer treated by SUS at Pérola Byington Hospital. The data were registered in the institution’s data collection system, based on the selection of all women diagnosed with breast cancer in the period from January 2011 to December 2016, and stratified by survival in relation to the initial clinical staging. Results: Our database consists of 620 patients in stage zero (DCIS), 2,479 patients in stage I, 3,998 in stage II, 3,082 in stage III and 353 patients in stage IV. The highest survival rate (98%) was observed in patients with ductal carcinoma in situ. In stage I patients, the 5-year survival rate was 94.7%. This result is slightly higher than that observed in stage II patients, where 90.6% of them had a survival of more than 5 years. In patients belonging to stages IIIA, IIIB and IIIC, the 5-year survival was 83%, 72% and 57%, respectively. Among the patients treated in stage IV, the 5-year survival rate was 55%. Conclusions: Among DCIS, 2% had recurrence and death within 5 years. Survival in patients belonging to stages I and II was 94.7% and 90.6%, respectively, which is very close, according to literature data. The survival of patients belonging to stages IIIA and IIIB exceeded 70%, indirectly showing the efficacy of locoregional and systemic therapy at SUS, which applies to stages IIIC and IV. These reports are unprecedented in the database of the Unified Health System of the Municipality of São Paulo, in a population that undergoes only opportunistic screening.

APA, Harvard, Vancouver, ISO, and other styles

Lin, Ya-Wen, Sou-Yi Chang, Chih-Chi Kuo, Cheng-Wen Hsiao, Chih-Hsiung Hsu, Yu-Ching Chou, and Yu-Lueng Shih. "Abstract 2575: NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Stage II patients"

Ying, Hongan, Jinfan Shao, Xijuan Xu, Wenfeng Yu, and Weiwen Hong. Perineural Invasion is an Indication of Adjuvant Chemotherapy in Node Negative Colorectal cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0103.

Full text

Abstract:

Review question / Objective: Perineural invasion (PNI) is a possible route for metastatic spread in various cancer types, including colorectal cancer (CRC). PNI is linked to poor prognosis. For patients with lymph node positive colorectal cancer, a number of large-scale RCT studies have confirmed that they can benefit from chemotherapy, but there are still many controversies about whether colorectal patients with negative lymph nodes need adjuvant chemotherapy. At present, there is a general consensus that patients with stage II colorectal cancer who have risk factors such as PNI+ need chemotherapy. However, there are many recent literatures that show that patients with stage II colorectal cancer with nerve invasion risk factors can not prolong the OS and DFS of patients. At the same time, chemotherapy increases the toxicity, economic and mental burden of patients. Therefore, we hope to write this review to summarize the current research findings and provide some clinical guidance on whether patients with lymph node negative colon cancer who have perineural invasion should receive chemotherapy. Condition being studied: Patients with high-risk such as PNI+ stage II colon cancer (CC) are recommended to undergo adjuvant chemotherapy (ACT). However, whether such patients can benefit from ACT remains unclear. And recently studies shown that, ACT had no significant benefit among patients with PNI.

APA, Harvard, Vancouver, ISO, and other styles

Disis, Mary L. Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada456015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Full text

APA, Harvard, Vancouver, ISO, and other styles

Disis, Mary L. Phase II Study of a HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab. Fort Belvoir, VA: Defense Technical Information Center, May 2010. http://dx.doi.org/10.21236/ada533841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Chen, Zhe, Weichao Wang, Haitao Ma, Nan Wang, and Jiaxi Li. Correlation of neutrophil to lymphocyte ratio and prognosis in patients with stage II-IV esophageal squamous cell carcinoma: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Disis, Mary L. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy. Fort Belvoir, VA: Defense Technical Information Center, May 2008. http://dx.doi.org/10.21236/ada486630.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Fang, Mei Lan, Lupin Battersby, Marianne Cranwell, Heather Cassie, Moya Fox, Philippa Sterlini, Jenna Breckenridge, Alex Gardner, and Thomas Curtin. IKT for Research Stage 8: Dissemination. University of Dundee, December 2022. http://dx.doi.org/10.20933/100001255.

Full text

Abstract:

In 2020, the University of Dundee initiated the development of an Open Research strategy. As part of this initiative, in February 2021 the University’s Library and Learning Centre together with Open Research Champions from the Schools of Health Sciences and Dentistry, formed an Open Research Working group. To build on the University’s open research policy and infrastructure, the purpose of the group was to facilitate ongoing research and development of best practice approaches for our interdisciplinary environment to make outputs, data and other products of our research publicly available, building on University of Dundee’s Open Research policy and infrastructure. Through informal consultations with academic staff and students, the Open Research Working Group found that: → access and reach of research findings can be amplified through effective knowledge mobilisation, and stakeholder and patient and public involvement; and → there was a need for guidance and resources on how-to implement knowledge mobilisation activities with and for stakeholders throughout the entire research process – from proposal development to project completion. In June 2021, the Open Research working group, in partnership with Simon Fraser University’s Knowledge Mobilization Hub began the development of an Integrated Knowledge Translation (IKT) Toolkit, with funding support from the University of Dundee’s Doctoral Academy and Organisational Professional Development. IKT is an approach to knowledge translation that emphasises working in an engaged and collaborative partnership with stakeholders throughout the research cycle in order to have positive impact. The aim was to co-produce evidence-informed, best practice learning materials on how-to: → maintain ongoing relationships between researchers, community stakeholders and decision-makers in research development and implementation; and → facilitate an integrated, participatory way of knowledge production whereby researchers, practitioners and other knowledge users can collaborate to co-generate new and accessible knowledge that can be utilised in contexts ranging from supporting community development to policy guidance for practice. The IKT Toolkit was informed by a focused evidence review and synthesis of published peer-reviewed and grey literature and consists of 8 knowledge briefs and a slide deck co-produced for use in any discipline or sector. Each knowledge brief provides practical guidance and resources to support an IKT process in each of eight key research stages: (i) Partnership Building; (ii) Generating Priorities and Ideas; (iii) Proposal development; (iv) Study Design; (v) Data Collection; (vi) Data Analysis; (vii) Reporting and (viii) Dissemination. The current knowledge brief provides IKT guidance on Research Stage 8: Dissemination.

APA, Harvard, Vancouver, ISO, and other styles

Fang, Mei Lan, Lupin Battersby, Marianne Cranwell, Heather Cassie, Moya Fox, Philippa Sterlini, Jenna Breckenridge, Alex Gardner, and Thomas Curtin. IKT for Research Stage 7: Reporting. University of Dundee, December 2022. http://dx.doi.org/10.20933/100001254.

Full text

Abstract:

APA, Harvard, Vancouver, ISO, and other styles

Fang, Mei Lan, Lupin Battersby, Marianne Cranwell, Heather Cassie, Moya Fox, Philippa Sterlini, Jenna Breckenridge, Alex Gardner, and Thomas Curtin. IKT for Research Stage 1: Partnership Building. University of Dundee, December 2022. http://dx.doi.org/10.20933/100001248.

Full text

Abstract:

In 2020, the University of Dundee initiated the development of an Open Research strategy. As part of this initiative, in February 2021 the University’s Library and Learning Centre together with Open Research Champions from the Schools of Health Sciences and Dentistry, formed an Open Research Working group. To build on the University’s Open Research policy and infrastructure, the purpose of the group was to facilitate ongoing research and development of best practice approaches for our interdisciplinary environment to make outputs, data and other products of our research publicly available. Through informal consultations with academic staff and students, the Open Research Working Group found that: → access and reach of research findings can be amplified through effective knowledge mobilisation, and stakeholder and patient and public involvement; and → there was a need for guidance and resources on how-to implement knowledge mobilisation activities with and for stakeholders throughout the entire research process – from proposal development to project completion. In June 2021, the Open Research working group, in partnership with Simon Fraser University’s Knowledge Mobilization Hub began the development of an Integrated Knowledge Translation (IKT) Toolkit, with funding support from the University of Dundee’s Doctoral Academy and Organisational Professional Development. IKT is an approach to knowledge translation that emphasises working in an engaged and collaborative partnership with stakeholders throughout the research cycle in order to have positive impact. The aim was to co-produce evidence-informed, best practice learning materials on how-to: → maintain ongoing relationships between researchers, community stakeholders and decisionmakers in research development and implementation; and → facilitate an integrated, participatory way of knowledge production whereby researchers, practitioners and other knowledge users can collaborate to co-generate new and accessible knowledge that can be utilised in contexts ranging from supporting community development to policy guidance for practice. The IKT Toolkit was informed by a focused evidence review and synthesis of published peer-reviewed and grey literature and consists of eight knowledge briefs and a slide deck co-produced for use in any discipline or sector. Each knowledge brief provides practical guidance and resources to support an IKT process in each of eight key research stages: (i) Partnership Building; (ii) Generating Priorities and Ideas; (iii) Proposal development; (iv) Study Design; (v) Data Collection; (vi) Data Analysis; (vii) Reporting and (viii) Dissemination. The current knowledge brief provides IKT guidance on Research Stage 1: Partnership Building.

APA, Harvard, Vancouver, ISO, and other styles

Fang, Mei Lan, Lupin Battersby, Marianne Cranwell, Heather Cassie, Moya Fox, Philippa Sterlini, Jenna Breckenridge, Alex Gardner, and Thomas Curtin. IKT for Research Stage 3: Proposal Development. University of Dundee, December 2022. http://dx.doi.org/10.20933/100001250.

Full text

Abstract:

In 2020, the University of Dundee initiated the development of an Open Research strategy. As part of this initiative, in February 2021 the University’s Library and Learning Centre together with Open Research Champions from the Schools of Health Sciences and Dentistry, formed an Open Research Working group. To build on the University’s open research policy and infrastructure, the purpose of the group was to facilitate ongoing research and development of best practice approaches for our interdisciplinary environment to make outputs, data and other products of our research publicly available, building on University of Dundee’s Open Research policy and infrastructure. Through informal consultations with academic staff and students, the Open Research Working Group found that: → access and reach of research findings can be amplified through effective knowledge mobilisation, and stakeholder and patient and public involvement; and → there was a need for guidance and resources on how-to implement knowledge mobilisation activities with and for stakeholders throughout the entire research process – from proposal development to project completion. In June 2021, the Open Research working group, in partnership with Simon Fraser University’s Knowledge Mobilization Hub began the development of an Integrated Knowledge Translation (IKT) Toolkit, with funding support from the University of Dundee’s Doctoral Academy and Organisational Professional Development. IKT is an approach to knowledge translation that emphasises working in an engaged and collaborative partnership with stakeholders throughout the research cycle in order to have positive impact. The aim was to co-produce evidence-informed, best practice learning materials on how-to: → maintain ongoing relationships between researchers, community stakeholders and decision-makers in research development and implementation; and → facilitate an integrated, participatory way of knowledge production whereby researchers, practitioners and other knowledge users can collaborate to co-generate new and accessible knowledge that can be utilised in contexts ranging from supporting community development to policy guidance for practice. The IKT Toolkit was informed by a focused evidence review and synthesis of published peerreviewed and grey literature and consists of 8 knowledge briefs and a slide deck co-produced for use in any discipline or sector. Each knowledge brief provides practical guidance and resources to support an IKT process in each of eight key research stages: (i) Partnership Building; (ii) Generating Priorities and Ideas; (iii) Proposal development; (iv) Study Design; (v) Data Collection; (vi) Data Analysis; (vii) Reporting and (viii) Dissemination. The current knowledge brief provides IKT guidance on Research Stage 3: Proposal Development.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

Academic literature on the topic 'Stage II patients'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Contents

Journal articles on the topic "Stage II patients"

Dissertations / Theses on the topic "Stage II patients"

Books on the topic "Stage II patients"

Book chapters on the topic "Stage II patients"

Conference papers on the topic "Stage II patients"

Reports on the topic "Stage II patients"